On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
This estimate on the “PrEP gap” in Europe was published in a paper in Eurosurveillance stating that 500 000 men who have sex with men in the European Union currently cannot access HIV pre-exposure prophylaxis (PrEP), despite being very likely to use it.
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
The Carnival season will last from 1 to 9 March 2019. In Rio de Janeiro, Brazil, 1 million participants are expected, including many travellers from Europe
The tools to end new HIV infections and AIDS exist. The knowledge on how to use them is agreed upon. Nevertheless late diagnosis of HIV remains a challenges across the European Union and European Economic Area.
From diagnosis of HIV to successful viral suppression: in a rapid communication published in Eurosurveillance, ECDC and co-authors from Public Health England and The National AIDS Trust summarise the progress towards HIV elimination in 52 countries in Europe and Central Asia. The main issues: diagnosing those who are unaware of their HIV infection and treating them.
With nearly 160 000 people newly diagnosed with HIV, 2017 marked another year of alarming numbers of new HIV diagnoses in the WHO European Region. In contrast, the European Union and European Economic Area (EU/EEA) countries reported a decline in rates of new diagnoses, mainly driven by a 20% decrease since 2015 among men who have sex with men.
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.